Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent.
Bis-acetato-ammine-dichloro-cyclohexylamine-platinum (IV), JM216, is the first antineoplastic platinum compound that can be given to patients orally. Several phase II clinical trials of JM216 monotherapy have already been reported. However, no information on the potential drug interactions caused by...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Nature Publishing Group|1
1998
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062991/ |